Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Insurance in an Era of Escalating Climate Risk
Climate change is happening, right here, right now. From record-breaking storms to heatwaves, the UK and Ireland are facing climate-driven risks tha
Pensions 2025 - Discussing the industry issues that matter
The annual Pensions UK Conference is always a highlight in the pensions industry events calendar. It’s great not just to hear the talks from the mover
TPR reminder on setting mortality base tables for pensions
Stephen Caine considers the importance of mortality base tables in light of the new funding regime. As many schemes prepare for their first valuations

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.